INmune Bio Inc.

Stand by, your program is about to begin. Greetings and welcome to the Immune Bio Third Quarter 2024 Earnings Call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this time, it is my pleasure to introduce Mr. David Moss, CFO of ImmuneBio. David.

Thank you, Chloe, and good afternoon, everyone. We thank you for joining us for the call for ImmuneBio's third quarter 2024 financial results. With me on the call today are Dr. RJ Tessie, CEO and co-founder of ImmuneBio, Dr. Mark Liddell, Chief Scientific Officer and co-founder of ImmuneBio, and Dr. C.J. Barnum, our head of neuroscience. Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those such as forward-looking statements. Please see the forward-looking statements disclaimer on the company's earnings press release, as well as the risk factors in the company's SEC filings, including our most recent quarter filing with the SEC. There's no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, MU-BIO disclaims any obligation to update these forward-looking statements to reflect future information events or circumstances. With the forward-looking statements behind us, it's now my pleasure to turn the call over to Dr. RJ Tessie. RJ.

Thank you, David, and good afternoon to everyone.